Newsroom

Medica 2022, Dusseldorf

Medica was an excellent opportunity to learn more about medical and healthcare innovations and interact with like-minded individuals in the industry.

Read More...

GeneFirst at NextGen Omics 2022

Earlier in November, GeneFirst’s Rick Bhatt and Dara McCreary attended the NextGen Omics event in London and are eager to share their highlights.

Read More...

Papilloplex HR-HPV test has non-inferior clinical performance for detection of human papillomavirus infection

GeneFirst has achieved another milestone this week with a clinical validation paper having been published under the VALidation of HPV GENotyping Tests (VALGENT) framework.

Read More...

GeneFirst COVID-19 kits and new Variant of Concern, Omicron

GeneFirst Limited confirms that its COVID-19 and COVID-19 Plus Detection Kits are able to detect the Omicron (B.1.1.529) variant.


GeneFirst has performed In silico analyses of the Omicron genome sequences publicly available on GISAID and confirms that the primers and probes included within the GeneFirst COVID-19 Detection Kits are not impacted by the mutations within the Omicron variant. 

Read More...

GeneFirst will be attending Medica 2021 in Düsseldorf

GeneFirst will be attending Medica 2021 in Dusseldorf, Germany this year as part of the Department for International Trade’s Delegation situated in Hall H, stand H16.


Ashay Patel, Business Development Manager and Becky Horne, Scientist for GeneFirst, will be attending the event. GeneFirst will be presenting theportfolio for both infectious diseasesand oncology testing including RT-PCR kits for the detection of COVID-19 and other respiratory tract infections, high risk HPV types (Papilloplex®), and in addition, XCeloSeq®, a broad range of NGS oncology products.



Read More...

Innovative UK SME GeneFirst and University of Leeds win £1.4M NIHR grant to clinically validate the use of a novel NGS based technology in bowel cancer screening

GeneFirst has teamed up with the Division of Pathology and Data Analytics at the University of Leeds to investigate the clinical utility of a novel NGS technology, Adaptor Temple Oligo-Mediated Sequencing (ATOM-Seq™), in bowel cancer screening and diagnostics. As the recipient of the highly competitive Invention for Innovation (i4i) funding from the National Institute of Health (NIHR), the aim of the project is to determine whether a sequencing-based assay for bowel cancer, testing either faecal tumour DNA or blood-derived cf/ctDNA (cell free/circulating tumour DNA), would be suited for the implementation into clinical use. [...]

Read More...

NEW publication on the utility of GeneFirst’s ATOM-Seq (TM) NGS library preparation technology for use with cfDNA and cfRNA

GeneFirst Limited is proud to have the recent paper titled Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-Sensitive UMI-based NGS librarypreparation technology for use with cfDNA and cfRNA accepted for publication by Scientific Reports. The paper is the [...]

Read More...

GeneFirst launches CE-IVD COVID-19 test kit.

GeneFirst develops Real-Time PCR tests for detection of the new coronavirus 2019-nCoV

In response to the recent outbreak of the new coronavirus 2019-nCoV, molecular diagnostics company, GeneFirst, has developed two real-time PCR tests for the detection of 2019-nCoV and other viruses.

Read More...

NEW publication on the analytical performance of Papilloplex HR-HPV

The accurate detection and genotyping of high-risk human papillomavirus (HR-HPV) is critical for cervical cancer screening and epidemiological investigations. GeneFirst Papilloplex® HRHPV is a new CE-IVD marked real-time PCR test, based on patented Multiplex Probe Amplification (MPA) technology. Papilloplex® HR-HPV provides the simultaneous detection and differentiation of 14 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68a/b) in a single closed-tube reaction ensuring rapid, cost effective and contamination free results. In this study, the analytical performance characteristics in terms of the assay’s sensitivity, specificity, range, reproducibility and cross-reactivity were evaluated. Papilloplex® HR-HPV provided sensitive detection and differentiation of 14 HR-HPV types with highly reproducible results. The differential HR-HPV specificity and sensitivity was further confirmed through the participation in the WHO HPV Laboratory Network Proficiency Study (2014). Overall, GeneFirst Papilloplex® HR-HPV assay demonstrated a robust analytical performance with reproducible and reliable results in the detection of HR-HPV genotypes.

GeneFirst wins €2.9m Horizon 2020 grant to deliver predictive diagnostic panel for HPV infections evolving into cervical cancer

Oxford, UK. GeneFirst Limited, the leader in delivering innovative solutions for HPV testing today announces the award of a €2.9 million up-front grant from the SME Instrument of the European Commission’s Horizon 2020 Programme to develop a predictive assay panel that can discriminate those hrHPV infections at increased risk of disease progression. This work will be conducted with GeneFirst’s joint collaborator, Hiantis S.r.l, based in Milan, Italy, who has extensive experience in clinical and laboratory research.

Read More...

GeneFirst wins second major Innovate UK competitive grant to improve cancer treatment using its ATOM-seq™ NGS technology

Oxford, UK. GeneFirst Limited, the leader in delivering Next Generation Sequencing solutions for liquid biopsy testing, today announces the award of a 12-month grant of £457,000 from Innovate UK’s Open Programme Round 3 to continue development of DNA sequencing technology to improve cancer treatment through better detection of cancer mutations in blood.

Read More...